{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:45:55Z","timestamp":1782499555344,"version":"3.54.5"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["NU50CK000574"],"award-info":[{"award-number":["NU50CK000574"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["DP2 AI176896"],"award-info":[{"award-number":["DP2 AI176896"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Since 2020, Infectious Diseases Society of America\/American Thoracic Society\/Centers for Disease Control and Prevention guidelines have preferentially recommended \u22644-month rifamycin-based regimens for tuberculosis infection. Since 2022, recommendations have included all-oral 6-month regimens (bedaquiline, pretomanid, and high-dose linezolid [BPaL] or BPaL plus moxifloxacin [BPaL-M]) for drug-resistant disease and a 4-month regimen (rifapentine, isoniazid, and moxifloxacin [HPMZ]) for drug-susceptible disease. Yet implementation of new regimens often lags behind guidelines. This survey aimed to characterize tuberculosis treatment practices of infectious disease clinicians and barriers to utilizing these regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A survey about tuberculosis treatment practices was distributed to 1501 North American adult infectious disease physician members of the IDSA's Emerging Infections Network. Percentages of respondents were calculated for each question. Open comment data were qualitatively analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three hundred forty-nine clinicians completed the survey. Ninety-three percent of respondents preferentially opted for \u22644-month regimens for tuberculosis infection, with only 12% expressing concerns about treatment effectiveness. In contrast, 1% selected HPMZ for pulmonary drug-susceptible disease, and 5% reported experience with HPMZ. For confirmed drug-resistant disease, 39% reported that they would use BPaL or BPaL-M, with 40% unsure about regimen choice. Forty-three percent reported uncertainty about effectiveness of 4- and 6-month regimens for drug-susceptible disease and drug-resistant disease. Qualitative analysis highlighted barriers to the use of newer regimens for tuberculosis disease, including concerns about treatment toxicities related to HPMZ or linezolid, medication interactions, and rifapentine and bedaquiline availability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While infectious disease physicians preferentially use shorter regimens for tuberculosis infection, uptake of newer regimens for tuberculosis disease is low due to concerns about effectiveness and treatment toxicities. Enhanced adverse effect management and monitoring and shared decision-making can optimize the implementation of newer tuberculosis disease treatment regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag330","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:48:55Z","timestamp":1781178535000},"source":"Crossref","is-referenced-by-count":0,"title":["Infectious Disease Provider Perspectives on Shorter Tuberculosis Treatment Regimens"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-8075","authenticated-orcid":false,"given":"Aliya","family":"Moreira","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Beth Israel Deaconess Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Hassneiah","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Beth Israel Deaconess Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-506X","authenticated-orcid":false,"given":"Susan E","family":"Beekmann","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Carver College of Medicine University of Iowa , Iowa City, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-5898","authenticated-orcid":false,"given":"Philip","family":"Polgreen","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Carver College of Medicine University of Iowa , Iowa City, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-2388","authenticated-orcid":false,"given":"Maunank","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3544-5021","authenticated-orcid":false,"given":"Ruvandhi R","family":"Nathavitharana","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Beth Israel Deaconess Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026062613472705500_ofag330-B1","author":"World Health Organization","year":"2026"},{"key":"2026062613472705500_ofag330-B2","author":"Centers for Disease Control and Prevention","year":"2024"},{"key":"2026062613472705500_ofag330-B3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31988","article-title":"Estimated health and economic outcomes of racial and ethnic tuberculosis disparities in US-born persons","volume":"7","author":"Swartwood","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026062613472705500_ofag330-B4","author":"World Health Organization"},{"key":"2026062613472705500_ofag330-B5","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1513\/AnnalsATS.201509-632PS","article-title":"Treatment of tuberculosis. A historical perspective","volume":"12","author":"Murray","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026062613472705500_ofag330-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2026062613472705500_ofag330-B7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis\u2014United States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026062613472705500_ofag330-B8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2026062613472705500_ofag330-B9","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"key":"2026062613472705500_ofag330-B10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017863","article-title":"Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis","volume":"5","author":"Seung","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026062613472705500_ofag330-B11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2026062613472705500_ofag330-B12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2026062613472705500_ofag330-B13","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang'wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2026062613472705500_ofag330-B14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026062613472705500_ofag330-B15","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2026062613472705500_ofag330-B16","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S2213-2600(23)00096-6","article-title":"Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis","volume":"11","author":"Winters","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026062613472705500_ofag330-B17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2026062613472705500_ofag330-B18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026062613472705500_ofag330-B19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12889-020-10098-5","article-title":"Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru","volume":"21","author":"Yuen","year":"2021","journal-title":"BMC Public Health"},{"key":"2026062613472705500_ofag330-B20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5588\/ijtld.23.0599","article-title":"Reasons for acceptance or nonparticipation in iAdhere: a trial of latent TB infection treatment","volume":"28","author":"Chapman Hedges","year":"2024","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026062613472705500_ofag330-B21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004401","article-title":"Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: a mathematical modeling analysis","volume":"21","author":"James","year":"2024","journal-title":"PLoS Med"},{"key":"2026062613472705500_ofag330-B22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000567","article-title":"The contribution of drug import to the cost of tuberculosis treatment: a cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan","volume":"2","author":"Kohler","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2026062613472705500_ofag330-B23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/cid\/cit932","article-title":"The Infectious Diseases Society of America Emerging Infections Network \u2013 bridging the gap between clinical infectious diseases and public health","volume":"58","author":"Pillai","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026062613472705500_ofag330-B24","doi-asserted-by":"crossref","first-page":"XXX","DOI":"10.1093\/ofid\/ofae178","article-title":"Experience with four-month rifapentine and moxifloxacin-based tuberculosis treatment in San Francisco","volume":"11","author":"Louie","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026062613472705500_ofag330-B25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5588\/ijtld.24.0616","article-title":"Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen","volume":"29","author":"Galvis","year":"2025","journal-title":"Int J Tuberc Lung Dis"},{"key":"2026062613472705500_ofag330-B26","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/cid\/ciac867","article-title":"Adverse events associated with treatment for pan-susceptible tuberculosis in San Francisco","volume":"76","author":"Louie","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026062613472705500_ofag330-B27","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/cid\/ciad312","article-title":"Implementation of bedaquiline, pretomanid, and linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant tuberculosis disease","volume":"77","author":"Haley","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026062613472705500_ofag330-B28","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/S1473-3099(24)00597-8","article-title":"Representativeness and adverse event reporting in late-phase clinical trials for rifampin-susceptible tuberculosis: a systematic review","volume":"25","author":"Burman","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026062613472705500_ofag330-B29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004438","article-title":"Research on the treatment of rifampin-susceptible tuberculosis\u2014time for a new approach","volume":"21","author":"Burman","year":"2024","journal-title":"PLoS Med"},{"key":"2026062613472705500_ofag330-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2026062613472705500_ofag330-B31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/FPC.0000000000000417","article-title":"Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine","volume":"31","author":"Haas","year":"2021","journal-title":"Pharmacogenet Genomics"},{"key":"2026062613472705500_ofag330-B32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/phar.2672","article-title":"Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management","volume":"42","author":"MacDougall","year":"2022","journal-title":"Pharmacotherapy"},{"key":"2026062613472705500_ofag330-B33","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1016\/S1473-3099(23)00496-6","article-title":"Questioning bedaquiline availability","volume":"23","author":"Holt","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026062613472705500_ofag330-B34","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00149-6","article-title":"Bedaquiline: what might the future hold?","volume":"5","author":"Shaw","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026062613472705500_ofag330-B35","author":"Treatment Action Group","year":"2024"},{"key":"2026062613472705500_ofag330-B36","author":"Treatment Action Group","year":"2024"},{"key":"2026062613472705500_ofag330-B37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/00187259.2023.2286173","article-title":"Connecting the DOTS: should we still be doing directly observed therapy?","volume":"83","author":"Stillo","year":"2024","journal-title":"Hum Organ"},{"key":"2026062613472705500_ofag330-B38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/M17-1150","article-title":"Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial","volume":"167","author":"Belknap","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026062613472705500_ofag330-B39","doi-asserted-by":"crossref","first-page":"e3459","DOI":"10.1093\/cid\/ciaa1364","article-title":"Higher completion rates with self-administered once-weekly isoniazid-rifapentine versus daily rifampin in adults with latent tuberculosis","volume":"73","author":"Haas","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026062613472705500_ofag330-B40","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/cid\/ciad659","article-title":"US guidelines fall short on short-course tuberculosis-preventive therapy","volume":"78","author":"Krishnan","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag330\/68517813\/ofag330.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag330\/68517813\/ofag330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/6\/ofag330\/68517813\/ofag330.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:47:38Z","timestamp":1782496058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag330\/8706982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag330","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"ofag330"}}